Claude Bertrand

Executive Vice President Research and Development at Servier, joined the Group in March 2017 and is member of Servier EXCOM. He held various positions at Ciba-Geigy in Basel, at Roche Bioscience in Palo Alto, California where he became head of the in vivo pharmacology group and was responsible for supporting projects in rheumatology and respiratory diseases. In 1999, he was recruited as Director of Biology for Inflammation, GI and Pain at Parke-Davies, where he was heading Drug Discovery. In 2004, Dr. Bertrand joined AstraZeneca as Vice-President Discovery for Respiratory & Inflammation Research at Alderley Park, UK and in 2005 was appointed Global Senior Vice President for Respiratory & Inflammation Research Area overseeing R&D activities at three sites in the UK and Sweden. In 2009, Dr. Bertrand joined Ipsen, France, as Executive Vice-President, Chief Scientific Officer and was since June 2011, Executive Vice-President for R&D, Chief Scientific Officer with a focus on Oncology, Neurology and Endocrinology. Dr Bertrand has published more than 70 papers in peer-reviewed journals, has authored 20 chapters and has presented more than 100 communications at scientific meetings. Since 1996, he has been a visiting lecturer for Ph.D. student programs at Universities in London, Strasbourg, Nancy, Rennes, Orleans and Paris.